Abstract:Tumor immunotherapy has emerged as a promising approach in cancer treatment in recent years, offering vast potential. This method primarily involves targeting and inhibiting the suppressive checkpoints present in different immune cells to enhance their activation, ultimately leading to tumor regression. However, tumor cells exploit the surrounding immune cells and tissues to establish a tumor microenvironment (TME) that supports their survival and growth. Within the TME, the efficacy of effector immune cells is compromised, as tumor cells exploit inhibitory immune cells to suppress their function. Furthermore, certain immune cells can be co-opted by tumor cells to facilitate tumor growth. While significantly enhancing the body's tumor immunity can lead to tumor regression, it can also result in severe toxic side effects and an inflammatory factor storm. As a consequence, patients often discontinue treatment due to immune-related adverse events (irAEs) or, in extreme cases, succumb to toxic side effects before experiencing tumor regression. In this analysis, we examined several remission regimens for irAEs, each with its own drawbacks, including toxic side effects or suppression of tumor immunotherapy, which is undesirable. A recent research study, specifically aimed at downregulating intestinal epithelial barrier permeability, has shown promising results in reducing the severity of inflammatory bowel disease (IBD) while preserving immune function. This approach effectively reduces the severity of IBD without compromising the levels of TNF-α and IFN-γ, which are crucial for maintaining the efficacy of tumor immunotherapy. Based on the substantial similarities between IBD and ICI colitis (combo immune checkpoint inhibitors-induced colitis), this review proposes that targeting epithelial cells represents a crucial research direction for mitigating irAEs in the future.

Improving the efficacy of immunotherapy for colorectal cancer: Targeting tumor microenvironment-associated immunosuppressive cells

Immunotherapy Combined with Local Therapy in the Late-Line Treatment of Repair-Proficient (pmmr)/microsatellite Stable (MSS) Metastatic Colorectal Cancer

How to overcome tumor resistance to anti-PD-1/PD-L1 therapy by immunotherapy modifying the tumor microenvironment in MSS CRC

The Role of the Tumor Microenvironment and Treatment Strategies in Colorectal Cancer

Immunotherapies catering to the unmet medical need of cold colorectal cancer

Improving the efficiency of immune checkpoint inhibitors for metastatic pMMR/MSS colorectal cancer: Options and strategies.

Immunotherapy with Immune Checkpoint Inhibitors for Advanced Colorectal Cancer: A Promising Individualized Treatment Strategy

Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions

Exploring immunotherapy in colorectal cancer

Tumor-Infiltrating Lymphocytes in Colorectal Cancer: The Fundamental Indication and Application on Immunotherapy

Targeting MSS colorectal cancer with immunotherapy: are we turning the corner?

Unveiling the Key Regulators

Immunotherapy of microsatellite stable colorectal cancer: resistance mechanisms and treatment strategies

Advances in targeting tumor microenvironment for immunotherapy

Immunotherapy combined with radiotherapy to reverse immunosuppression in microsatellite stable colorectal cancer

Current Status and Future Perspective of Immune Checkpoint Inhibitors in Colorectal Cancer.

Gutting it Out: Developing Effective Immunotherapies for Patients With Colorectal Cancer

Progress in the Application of Immune Checkpoint Inhibitor-Based Immunotherapy for Targeting Different Types of Colorectal Cancer

Immunotherapy for colorectal cancer:current status, challenges and solution

Immunotherapy in colorectal cancer: rationale, challenges and potential

Tumor-Associated Neutrophils in Colorectal Cancer Development, Progression and Immunotherapy